Locke Lord Represents Juvenescence in Launch of Latest Joint Venture Project With FoxBio
A Locke Lord team comprised of Douglas Gray (Providence) and Ralph Loren (Boston) represented Juvenescence Limited, a leading drug development company based in the British Virgin Islands, focused on the development of therapies to increase human longevity, in connection with the launch of its latest joint venture project, FoxBio Inc. Juvenescence will support FoxBio with $10 million in equity financing and drug development capabilities. Juvenescence’s partner in the joint venture, Antoxerene Inc. (a portfolio company of Ichor Therapeutics, Inc.), is a leading small molecule developer.
Posted on November 1, 2018
RELATED PROFESSIONALS
RELATED SERVICES
Disclaimer
Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.